CT2070/2026 - FRAMEWORK CONTRACT FOR THE SUPPLY OF CANAKINUMAB 150MG/ML SOLUTION FOR INJECTION
TED · 394232-2026Award noticeawardedNo deadline given
Value
Estimated€10,547,578 · 10,547,578 EUR
Awarded€10,056,992 · 10,056,992.4 EUR
WinnerV.J. Salomone Pharma Limited
Who already wins at this buyer
Firms with recorded awards from Department of Contracts in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| E.J. BUSUTTIL LIMITED | 7 | €2,953,933 | 2026-06-25 |
| Drugsales Ltd | 3 | €2,659,922 | 2026-06-11 |
| V.J. Salomone Pharma Limited | 3 | €1,810,895 | 2026-06-24 |
| Mint Health Limited | 3 | €1,145,101 | 2026-06-09 |
| Evolve Ltd. | 2 | €1,613,879 | 2026-06-24 |
Full buyer profile: what Department of Contracts buys and who wins it →
CPV codes
33690000 Medical equipment & pharmaceuticalsDescription
CT2070/2026 - FRAMEWORK CONTRACT FOR THE SUPPLY OF CANAKINUMAB 150MG/ML SOLUTION FOR INJECTION
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-07-01 | CT2184/2026 - FRAMEWORK CONTRACT FOR THE SUPPLY OF NATALIZUMAB 300MG CONCENTRATE FOR SOLUTION FOR INFUSION | Department of Contracts MT | 93% |
| 2026-07-01 | CT2212/2026 - FRAMEWORK CONTRACT FOR THE SUPPLY OF RITUXIMAB 10MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION | Department of Contracts MT | 93% |
| 2026-05-06 | CT2296/2025 - Framework Contract for the supply of Brentuximab 50mg powder for concentrate for solution for injection | Department of Contracts MT | 93% |
| 2026-06-30 | CT2199/2026 - Framework Contract for supply of Doxapram Hydrochloride 20mg/mL Solution for Injection | Department of Contracts MT | 93% |
| 2026-04-30 | CT2096/2026 - FRAMEWORK CONTRACT FOR THE SUPPLY OF INSULIN DEGLUDEC 100 IU/ML SOLUTION FOR INJECTION | Department of Contracts MT | 92% |
| 2026-06-03 | CT2377/2025 - Framework Contract for the supply of Ustekinumab 45mg Solution for Injection, Ustekinumab 90mg Solution for Injection , and Ustekinumab 130mg Concentrate for Solution for Infusion | Department of Contracts MT | 92% |